Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Wall Street Analysts Boost Take-Two Price Targets Amid Strong Gaming Performance

Robert Sasse by Robert Sasse
November 4, 2025
in Analysis, Gaming & Metaverse, Tech & Software
0
Take-Two Stock
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

Financial analysts are expressing renewed confidence in Take-Two Interactive, with multiple firms significantly raising their price targets for the gaming company’s shares. This optimistic shift comes despite recent stock performance challenges and highlights the enduring strength of key franchises.

Upgraded Forecasts from Major Institutions

Several prominent investment banks have revised their outlook on Take-Two. Jefferies increased its price target from $270 to $300 while maintaining a buy recommendation. TD Cowen established a $284 target, with both Benchmark and DA Davidson projecting the stock could reach $300. This collective bullish stance reflects growing confidence in the company’s core business segments.

The primary drivers behind this analyst enthusiasm appear to be the consistently strong performance of the NBA 2K series and robust mobile gaming results. These two revenue streams are expected to provide stability during fluctuating market conditions.

Quarterly Expectations and Financial Metrics

Market attention now turns to upcoming quarterly results, where analysts anticipate substantial year-over-year improvements. The consensus projection points to earnings of $0.91 per share, representing significant growth of 37.9% compared to the same period last year. Revenue expectations are equally optimistic, with forecasts targeting $1.74 billion.

Should investors sell immediately? Or is it worth buying Take-Two?

Notably, financial experts have upwardly revised their profit estimates by 10% over the past month. Key performance indicators under scrutiny include:

  • Total Net Bookings: $1.73 billion (previous year: $1.47 billion)
  • Digital Bookings: $1.63 billion projected
  • Console Segment: $813.85 million forecast
  • Mobile Gaming: $734.59 million anticipated
  • International Markets: Growth to $672.68 million expected

Market Performance and External Factors

Despite the positive analyst sentiment, Take-Two shares have recently demonstrated relative weakness. While the S&P 500 index gained 2.4% over the past month, Take-Two declined by 0.5%. Additional pressure emerged from broader market softness, including a November 4th dip in the US500 index.

Other developments creating market uncertainty include the November 3rd launch of the restructured NBA 2K League and ongoing criticism directed at Rockstar Games regarding alleged anti-union practices. Whether strong fundamental performance will outweigh these secondary concerns should become clearer when quarterly figures are officially released.

Ad

Take-Two Stock: Buy or Sell?! New Take-Two Analysis from March 25 delivers the answer:

The latest Take-Two figures speak for themselves: Urgent action needed for Take-Two investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Take-Two: Buy or sell? Read more here...

Tags: Take-Two
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Gossamer Bio Stock
Analysis

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

March 25, 2026
SOXX ETF Stock
Commodities

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock
Analysis

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Next Post
Kraft Heinz Stock

Kraft Heinz Shares Tumble Amid Consumer Spending Crisis

Realty Income Stock

European Expansion Fuels Realty Income's Growth Trajectory

Super Micro Computer Stock

All Eyes on Super Micro's Earnings Release After Revenue Warning

Recommended

Lockheed Martin Stock

Defense Giant Lockheed Martin Secures Billions in New Military Contracts

6 months ago
OKE stock news

Amalgamated Bank Increases Stake in CF Industries as Market Opinions Vary

3 years ago
IBM Stock

IBM’s AI Windfall Fails to Impress Stock Market

7 months ago
Blackstonecured Lending Fund Stock

Blackstone BDC Insider Purchase Defies Analyst Downgrades

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Figma Embraces Third-Party AI to Power Its Design Ecosystem

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

Evolent Health Bets on AI Leadership Amid Share Price Decline

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Trending

Gossamer Bio Stock
Analysis

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

by Kennethcix
March 25, 2026
0

The future of Gossamer Bio hinges on a critical regulatory discussion scheduled for June 2026. The biopharmaceutical...

SOXX ETF Stock

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Figma Stock

Figma Embraces Third-Party AI to Power Its Design Ecosystem

March 25, 2026
BioNano Genomics Stock

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026
  • Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns
  • Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com